With EU nod, Biogen is ready to roll Tecfidera onto the continent

Biogen Idec's ($BIIB) fast-selling new multiple sclerosis drug won approval in a broad new market: Europe. After sewing up its Tecfidera intellectual property rights there last year, Biogen can now roll out the drug for first-line MS treatment across the continent. But as CEO George Scangos has pointed out, the EU launch won't yield sales results as immediately as the U.S. launch did, because Tecfidera has to win reimbursement in individual countries, a process that takes time. Release

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.